🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Dexcom CFO unloads $85.7k in company stock

Published 2024/06/12, 00:44

DexCom Inc. (NASDAQ:DXCM) reported that EVP and Chief Financial Officer Jereme M. Sylvain sold 745 shares of the company's common stock on June 10, according to a recent SEC filing. The transaction was executed at an average price of $115.05 per share, totaling approximately $85,712.

The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). The company's equity incentive plans mandate this type of transaction, known as a "sell to cover," to meet tax requirements. It is important to note that this sale does not represent a discretionary trade by Sylvain.

Following this transaction, Sylvain's direct ownership in DexCom includes 84,948 shares. This figure includes 50,549 unvested RSUs, some of which are set to vest over the coming years up to March 8, 2027. Additionally, the total includes 159 shares purchased under the DexCom, Inc. 2015 Employee Stock Purchase Plan.

DexCom, headquartered in San Diego, California, specializes in the development of glucose monitoring systems for diabetes management. The company's stock transactions by executives are closely watched by investors, as they can provide insights into the company's performance and leadership's confidence in the business's future.

In other recent news, DexCom, a frontrunner in continuous glucose monitoring (CGM) systems, has been making significant strides. The company reported a robust 25% organic revenue growth year-over-year in the first quarter, with total revenue reaching $921 million. DexCom also announced the upcoming launch of Stelo, its first over-the-counter CGM product, and raised its full-year revenue guidance to a range of $4.20 billion to $4.35 billion.

In addition to financial growth, DexCom has launched a feature allowing its Dexcom (NASDAQ:DXCM) G7 CGM System to connect directly to Apple (NASDAQ:AAPL) Watch, making it the first CGM system to offer real-time glucose readings on a user's wrist without the need for an iPhone. This feature is currently available to Dexcom G7 users in the United States, United Kingdom, and Ireland.

On the analyst front, Oppenheimer maintained its Outperform rating for DexCom amid recent developments in the CGM market, while Redburn-Atlantic initiated coverage with a Neutral rating, setting a price target for DexCom shares at $130.00. Both firms highlighted the potential market opportunity for DexCom's products, given the large untapped market segments beyond intensive insulin users. However, they also noted future growth may come with higher risks due to competition and pricing pressures.

InvestingPro Insights

DexCom Inc. (NASDAQ:DXCM) has been navigating a dynamic market landscape, and recent data from InvestingPro provides a deeper look into the company's financial health and market performance. With a market capitalization of $46.47 billion and a notable revenue growth of 25.78% in the last twelve months as of Q1 2024, DexCom shows a robust upward trajectory in its financials. The company's gross profit margin stands strong at 62.82%, reflecting its ability to maintain profitability in the competitive medical technology sector.

One of the InvestingPro Tips highlights that DexCom is trading at a low P/E ratio relative to near-term earnings growth, which could indicate that the stock is currently undervalized based on its earnings potential. Additionally, management's aggressive share buyback strategy is a signal that the company's leadership is confident in its future prospects and committed to delivering shareholder value.

Investors also keep a close eye on the PEG ratio, which for DexCom stands at 0.62, suggesting that the company's stock price is potentially undervalued relative to its earnings growth expectations. The Price / Book ratio is high at 20.63, which may be a point of consideration for value-focused investors. With these metrics in mind, coupled with the fact that analysts predict DexCom will be profitable this year, the company appears to be positioned for continued success.

For those interested in a deeper dive into DexCom's performance and future outlook, InvestingPro offers additional tips and insights. There are 13 more InvestingPro Tips available, providing a comprehensive analysis of the company's financials and market position. To access these insights and enhance your investment strategy, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.